Search for content, post, videos

Category

Pharma Diagnostics

CEO_Tuomas_Tenkanen_GeneSpress
0 COMMENT
88 Views
Mobidiag’s brand hits shelves in Italy

Under the three-year agreement, AB ANALITICA is the exclusive distributor of Mobidiag’s brand Amplidiag in vitro diagnostics for gastrointestinal infections in Italy. AB Analitica is specialized in the development and the sale of diagnostic systems for professional use. “For the past months, we have been significantly extending our in vitro…

signing-agreement
0 COMMENT
65 Views
Vironova signs agreement with the FDA

Vironova signs one-year agreement with the U.S. Food and Drug Administration to beta test proprietary Vironova Analyzing Software (VAS). In one of the fastest growing drug development areas today, nano-particles (for example liposomes), visible using electron microscopy, are used to deliver drugs to their exact targets in the body. Vironova…

immunovia
0 COMMENT
59 Views
Data from Immunovia’s new study announced

Immunovia has announced that the principal aim of a large retrospective study, performed in collaboration with Lund University’s IDEA Centre, has been achieved. The data confirms that IMMray biomarker signatures can distinguish Systemic Lupus Erythematosus (SLE) from three other main autoimmune diseases, rheumatoid arthritis, Sjögren’s disease and vasculitis with an…

agreement
0 COMMENT
59 Views
Gyros signs distribution agreement

Gyros Protein Technologies has appointed Abacus ALS as exclusive distributor of its immunoassay products in Australia and New Zealand. Abacus ALS, an ISO 9001: 2008 accredited organization, is one of Australia’s and New Zealand’s largest privately owned companies serving customers in the diagnostic pathology, research and healthcare education industries. Abacus…

fimmic-team
0 COMMENT
107 Views
New era for cancer diagnostics

Liquid biopsies, sequencing and upgraded software tools are among some of the recent and ongoing trends in cancer diagnostics. Developments in the diagnostic sector have vastly improved the ability to identify cancer diseases at the early stages of tumor formation. However, several cancer types cannot be identified early enough, while…

acarix_ceo
0 COMMENT
27 Views
Acarix to Nasdaq First North

Acarix applies for entry on Nasdaq First North Premier in Stockholm. The capital contribution which the company pertain to obtain in connection to the entry is worth 140 million SEK, already secured through description and garantee undertakings. The capital from the entry will mainly go to the company’s commercialization strategy…

acarix_ceo
0 COMMENT
32 Views
Acarix receives double-digit SEK million investment

Acarix, a Swedish/Danish medical device company specializing in non-invasive, non-radiation acoustic detection of Coronary Artery Disease (CAD), has received a major strategic investment from the Chinese company Puhua Jingxin Guzhou Health Management Partnership (Puhua Jingxin). The aim of the double-digit million investment is to accelerate market introduction of the already…

saromics
0 COMMENT
37 Views
SARomics signs distribution agreement

SARomics Biostructures has entered into a collaborative distributorship agreement with Carna Biosciences to provide its crystallography and protein structure determination services in Japan. Under the terms of the agreement, Carna Biosciences will be the exclusive distributor for SARomics’ co-crystallography services on the Japanese market. The agreement also encompasses non-exclusive distribution in China, Korea, Canada and…

Jan Stålmark
0 COMMENT
18 Views
AroCell apply for listing on Nasdaq

The Board of Directors of AroCell AB have decided to apply for listing of the company shares to trading on the Nasdaq First North exchange, and thereby change market for share listing. The change of market listing is planned to take place at the turn of the month June/July 2016,…

senzagen
0 COMMENT
22 Views
SenzaGen establishes subsidiary in the US

To quickly strengthen its commercial presence in the US market, Swedish SenzaGen AB expands globally and establishes a subsidiary in California. SenzaGen, which develops and implements non-animal allergy tests of chemicals and proteins, for the chemical, pharmaceutical and cosmetic industries, expands its sales organization and prepares the company for an…

immunovia
0 COMMENT
32 Views
Immunovia in new collaboration

Immunovia and the University of Liverpool enter into collaboration to validate early detection blood test for pancreatic cancer in a prospective clinical study. In line with Immunovia´s strategy to deliver the first validated test for early diagnosis of pancreatic cancer, the company announced yesterday that the first European site participating…

ernst westman
0 COMMENT
26 Views
Boule Diagnostics in new agreement

Boule Diagnostics AB has signed a distribution agreement with the American company Medica Corporation Inc., to promote and sell their EasyRA product in the United States. EasyRA is a system for clinical chemistry used to assist in patient diagnosis and determine problems, related to for example liver, kidney function and…

anne kihlborg
0 COMMENT
30 Views
Dynamic Code receives SEK 3 million from VINNOVA

Swedish Dynamic Code, developing DNA tests, has been givinga SEK 3 million funding from Vinnova. According to the company, the money will be spent on developing a new overall plan for future health tests simply used at home. The project goes under the name Dynamichealthcare.se. At the site customers will…

0 COMMENT
14 Views
Center to Focus on Lyme Disease

Uppsala University Hospital’s infectious disease unit is launching a pilot project to evaluate and treat patients with protracted, chronic pain and to determine if they have Lyme disease or another insect-borne illness. The center is scheduled to start accepting referrals Sept. 15 and pilot projects begin Oct. 6. “The target…